000145570 001__ 145570
000145570 005__ 20260112133352.0
000145570 0247_ $$2doi$$a10.3390/antibiotics13111011
000145570 0248_ $$2sideral$$a140370
000145570 037__ $$aART-2024-140370
000145570 041__ $$aeng
000145570 100__ $$0(orcid)0000-0001-5750-3643$$aPeris, María Paz$$uUniversidad de Zaragoza
000145570 245__ $$aDetection of Chlamydia trachomatis and Neisseria gonorrhoeae (and Its Resistance to Ciprofloxacin): Validation of a Molecular Biology Tool for Rapid Diagnosis and Treatment
000145570 260__ $$c2024
000145570 5060_ $$aAccess copy available to the general public$$fUnrestricted
000145570 5203_ $$aBackground and Objectives: Neisseria gonorrhoeae and Chlamydia trachomatis can cause similar clinical syndromes and may coexist in infections. In emergency medicine, empirical treatment targeting both pathogens is often employed, potentially contributing to antibiotic resistance. Gonococcal resistance has emerged against first-line antimicrobials, necessitating prior testing for fluoroquinolone susceptibility. Certest Biotec developed two molecular diagnostic products for simultaneous detection: VIASURE C. trachomatis & N. gonorrhoeae Real-Time PCR Detection Kit and VIASURE Neisseria gonorrhoeae Ciprofloxacin-Resistant Real-Time PCR Detection Kit. To evaluate these products, clinical performance assessments were conducted at the Clinical Microbiology Laboratory of Miguel Servet University Hospital in Zaragoza, Spain. Results and Conclusions: Both VIASURE assays under study demonstrated high clinical sensitivity and specificity compared to reference molecular assays and Sanger sequencing. These kits offer an accurate diagnosis, facilitating appropriate treatment choices while addressing concerns about emerging antibiotic resistance. Methods: A total of 540 clinical samples from 540 patients already characterized as positive or negative for CT and NG by a molecular assay and by antibiotic susceptibility testing for ciprofloxacin using a concentration gradient diffusion method were used for the clinical evaluation. In cases where sensitivity results were unavailable, conventional PCR and Sanger sequencing were employed.
000145570 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000145570 590__ $$a4.6$$b2024
000145570 592__ $$a1.114$$b2024
000145570 591__ $$aPHARMACOLOGY & PHARMACY$$b57 / 352 = 0.162$$c2024$$dQ1$$eT1
000145570 593__ $$aBiochemistry$$c2024$$dQ1
000145570 591__ $$aINFECTIOUS DISEASES$$b17 / 137 = 0.124$$c2024$$dQ1$$eT1
000145570 593__ $$aInfectious Diseases$$c2024$$dQ1
000145570 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2024$$dQ1
000145570 593__ $$aMicrobiology (medical)$$c2024$$dQ1
000145570 593__ $$aPharmacology (medical)$$c2024$$dQ1
000145570 593__ $$aMicrobiology$$c2024$$dQ2
000145570 594__ $$a8.7$$b2024
000145570 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000145570 700__ $$0(orcid)0000-0003-2742-8827$$aAlonso, Henar
000145570 700__ $$aEscolar, Cristina
000145570 700__ $$aTristancho-Baró, Alexander
000145570 700__ $$aAbad, María Pilar
000145570 700__ $$aRezusta, Antonio
000145570 700__ $$aMilagro, Ana
000145570 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000145570 773__ $$g13, 11 (2024), 1011 [12 pp.]$$pAntibiotics$$tAntibiotics$$x2079-6382
000145570 8564_ $$s288765$$uhttps://zaguan.unizar.es/record/145570/files/texto_completo.pdf$$yVersión publicada
000145570 8564_ $$s2795334$$uhttps://zaguan.unizar.es/record/145570/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000145570 909CO $$ooai:zaguan.unizar.es:145570$$particulos$$pdriver
000145570 951__ $$a2026-01-12-13:19:30
000145570 980__ $$aARTICLE